Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine headlines to help you catch up and stay informed. It was a busy week with lots of news, have a look and see you next week for another update.
Alberta 1st Province to Regulate Psychedelic Therapy
In big news for access to mental health treatments, Alberta has become the first Canadian province to regulate the use of psychedelics for therapy treatment.
Last Wednesday, the province announced amendments to the Mental Health Services Protection Act, including changes to rules around opioids prescriptions for people with addiction and the amendments to psychedelic use.
PharmaTher Granted U.S. Patent Covering Ketamine for Parkinson’s
Fabio Chianelli, CEO of PharmaTher: “We are pleased with the USPTO grant of the patent covering ketamine in the treatment of Parkinson’s disease and motor disorders. The US patent strengthens our intellectual property portfolio covering novel uses and delivery forms of ketamine. We are advancing the clinical development of ketamine in the treatment of levodopa-induced dyskinesia in patients with Parkinson’s disease, and we are seeking FDA agreement on pursuing approval under the 505(b)(2) regulatory pathway with a potential Phase 3 clinical study.”
atai Life Sciences Announces First Subject Dosed in Phase 1 Trial of DMT
“Exploring novel approaches to drug delivery can potentially simplify in-clinic administration and allow greater pharmacokinetic control of the psychedelic experience and its overall duration of hallucinogenic effects,” said Srinivas Rao, Chief Scientific Officer of atai Life Sciences. “We’re pleased to see this trial move forward as we establish the safety and tolerability of our compound.”
atai anticipates Phase 1 topline results in H1 2023.
Numinus Develops Mushroom Tea for Use in Psychedelic Research
The research behind the tea bag involved the development of processes and procedures to deliver 25mg per dose and the use of Numinus’ validated strains of Psilocybe cubensis. The tea bag will be studied in a phase 1 trial of practitioners receiving experiential training for psilocybin-assisted therapy, with the goal to be used in Numinus’ research, including trial partnerships at Cedar Clinical Research, Numinus’ clinical trial management division. The product has also been submitted to Health Canada to be included on the psilocybin supplier list for the federal Special Access Program.
Mindset Pharma Selects Lead Clinical Candidates From “Family 2” of its Next Generation Psychedelic Drug Portfolio
MSP-2020 and MSP-2003, exhibiting a stronger and shorter acting psychedelic effect than psilocybin in preclinical testing, are selected for IND enabling studies
